Physics

Internal medicine

Immunotherapy

Disease

Pembrolizumab

Incidence (geometry)

Biology

Gene

Optics

Cancer

Oncology

Intensive care medicine

Allele

Endometrial cancer

Microsatellite instability

Gynecology

Food and drug administration

Radiation therapy

Clinical trial

Biochemistry

Microsatellite

Medicine

Pharmacology

CA A Cancer Journal for Clinicians

Endometrial cancer is the most common gynecologic cancer in the United States, and its incidence is rising. Although there have been significant recent advances in our understanding of endometrial cancer biology, many aspects of treatment remain mired in controversy, including the role of surgical lymph node assessment and the selection of patients for adjuvant radiation or chemotherapy. For the subset of women with microsatellite‐instable, metastatic disease, anti– programmed cell death protein 1 immunotherapy (pembrolizumab) is now approved by the US Food and Drug Administration, and numerous trials are attempting to build on this early success.

Current recommendations and recent progress in endometrial cancer